Viking: 3 Key Takeaways for Long-Term Investors

Source The Motley Fool

Key Points

  • Viking initiated phase 3 trial testing for its oral weight-loss tablet.

  • Subcutaneous VK2735 achieved up to 22% weight loss in maintenance trials.

  • Viking raised $575 million, increasing cash holdings to $960 million.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

On its third-quarter 2026 earnings call, held on Oct. 28, 2026, Viking (NASDAQ:VKTX) announced the initiation of phase 3 registration trials (the final stage of human clinical testing required before regulatory approval) for its oral weight-loss tablet. Advancing oral and injectable formulations of its obesity drug candidate creates multiple commercial opportunities in a growing market. Three takeaways from management's comments highlight the key developments.

1. Oral VK2735 Advances Into Phase 3 Late-Stage Testing

Viking initiated its SUNRISE phase 3 registration program to evaluate daily oral tablet doses of VK2735, a dual GLP-1 and GIP receptor agonist that targets hormone pathways regulating appetite. If successful, this pill would offer patients a convenient daily alternative to weekly injections.

And earlier this month, we announced the initiation of the SUNRISE Phase III registration program.
-- Brian Lian, President and Chief Executive Officer

2. Maintenance Studies Show Weight Loss Retention With Less Frequent Dosing

Patients receiving subcutaneous injections (shots administered under the skin) maintained most of their initial weight loss when transitioning from weekly to biweekly or monthly dosing. Less frequent schedules can lower treatment costs and improve long-term patient compliance.

In this study, participants receiving VK2735 successfully maintained the majority of their initial weight loss following the transition to every other week or monthly dosing schedules.
-- Brian Lian, President and Chief Executive Officer

3. Capital Raise Secures $960 Million Cash Runway for Launch Preparation

Viking closed stock and convertible note offerings during the quarter, generating $575 million in gross proceeds and expanding total cash to $960 million. The fresh capital funds ongoing phase 3 trials and the preparation for early commercial manufacturing.

These funds substantially increase our financial runway and will support the ongoing development of all programs as well as the company's growing commercial operations and launch plans.
-- Brian Lian, President and Chief Executive Officer

Looking Ahead

Clinical execution is accelerating across both oral and subcutaneous programs, giving Viking distinct options in a competitive field. The company is building out commercial leadership, expanding supply chain capabilities, and focusing on pricing discipline ahead of potential market entry. Dosing flexibility offers a distinct structural advantage over competitors.

Having the ability to dose weekly, every other week or monthly, I think, imparts flexibility that others cannot offer at this point, and we don't see in the market today.
-- Brian Lian, President and Chief Executive Officer

With four phase 3 trials underway and $960 million on the balance sheet, Viking possesses the resources and clinical scope needed to advance its obesity portfolio toward commercialization.

Viking is now well positioned to advance its ongoing clinical programs and to continue working to deliver a broad portfolio of therapeutic formulation and dosing options to best support a personalized, convenient and sustainable weight loss program for people living with obesity.
-- Brian Lian, President and Chief Executive Officer

Should you buy stock in Viking Therapeutics right now?

Before you buy stock in Viking Therapeutics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*

Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 17, 2026.

The Motley Fool has positions in and recommends Viking Therapeutics. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Nvidia reports tomorrow with an interim CEO — $108 billion is the easy numberNvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
Author  Irene Q.
Yesterday 02: 11
Nvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
placeholder
Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
Author  Irene Q.
Yesterday 02: 27
Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
placeholder
Weekly Report: The index rose 2.5% while Nvidia fell 12.7% — two equity divergences, one should closeThe S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
Author  Irene Q.
Yesterday 02: 35
The S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 16, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
Author  Mitrade
Yesterday 02: 45
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
placeholder
Weekly Report: DXY 103.41, 10-year 5.15%, AUD carry 3bp — three FX regimes flipped in one weekThe dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
Author  Irene Q.
Yesterday 03: 26
The dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
goTop
quote